Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC – Research Report), Apollomics (APLM – Research Report) and Iterum Therapeutics (ITRM – Research Report) with bullish sentiments.

CalciMedica (CALC)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on CalciMedica today and set a price target of $20.00. The company’s shares closed last Thursday at $4.16.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 19.2% and a 49.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Cadrenal Therapeutics, Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CalciMedica with a $18.67 average price target.

See today’s best-performing stocks on TipRanks >>

Apollomics (APLM)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Apollomics today and set a price target of $5.00. The company’s shares closed last Thursday at $0.75, close to its 52-week low of $0.52.

According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -20.5% and a 25.4% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Calidi Biotherapeutics.

Apollomics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

Iterum Therapeutics (ITRM)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Iterum Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $1.54.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.5% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Iterum Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CALC:

• CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
• CalciMedica presented preclinical data from studies of Auxora in acute AKI
• CalciMedica initiated with a Buy at JonesResearch
• CalciMedica Advances Auxora in Kidney Injury Trial
• CalciMedica: FDA clears IND application for Phase 2 trial of Auxora